Drugs / MVA AMA1
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01351948 | Jun 2011 → Mar 2013 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01095055 | Mar → Oct 2010 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01142765 | Jun 2010 → Mar 2011 | malaria | University of Oxford | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01739036 Comparator | Jan → Oct 2013 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA AMA1 | “Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.” NCT01739036 ↗ |
| Modality | Vaccine | “the chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) replication-deficient viral vectored vaccines” PMID 22363582 ↗ Feb 2012 |
| Route | Intramuscular | “single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly” NCT01095055 ↗ |